Debbie Foley, DO
Rheumatology · Tulsa, OKNPI 1134140924
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $213,188 of the $280,819 with a category attached, or 75.9%. 33 manufacturers reported payments, led by Amgen at 49.0% of the total. Among rheumatology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,707 payments — averaging $164.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$138K
- AbbVie$93K
- Bristol Myers Squibb$27K
- Johnson & Johnson$10K
- AstraZeneca$2K
- UCB, Inc.$2K
- plus $9K from 27 others
Across 27 payments — averaging $8241.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$138K
- Novartis$49K
- AbbVie$33K
- Janssen Research & Development, LLC$3K
What the payments were for
- Consulting fees$11,6634%
- Speaking & faculty fees$213,18876%
- Travel & lodging$23,5368%
- Food & beverage$31,88011%
- Education$5520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 404 | $137,527 |
| AbbVie | 374 | $93,086 |
| Bristol Myers Squibb | 39 | $26,785 |
| Johnson & Johnson | 137 | $10,210 |
| AstraZeneca(2 entities) | 98 | $2,305 |
| UCB, Inc. | 123 | $2,008 |
| Pfizer | 104 | $1,327 |
| Lilly USA, LLC | 74 | $1,298 |
| Mallinckrodt Hospital Products Inc. | 57 | $1,252 |
| Novartis | 71 | $1,077 |
| E.r. Squibb & Sons, L.L.C. | 62 | $900 |
| Genentech USA, Inc. | 29 | $512 |
| Boehringer Ingelheim | 22 | $397 |
| Fresenius Kabi USA, LLC | 24 | $376 |
| Radius Health, Inc. | 15 | $249 |
| Aurinia Pharma U.S., Inc. | 13 | $229 |
| ANI Pharmaceuticals, Inc. | 11 | $217 |
| Sanofi | 6 | $193 |
| Mallinckrodt Enterprises LLC | 10 | $153 |
| GSK | 9 | $140 |
| Janssen Scientific Affairs, LLC | 2 | $132 |
| Actelion Pharmaceuticals US, Inc. | 5 | $126 |
| Sandoz | 3 | $66 |
| Antares Pharma, Inc. | 4 | $58 |
| Pacira Therapeutics, Inc. | 3 | $46 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Zimmer Biomet | 1 | $21 |
| Octapharma USA, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$280,819 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 24 | $190,449 |
| OtezlaApremilast | 19 | $99,302 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $61,275 |
| ActemraTocilizumab | 13 | $29,758 |
| Hydroxychloroquine Sulfate | 409 | $16,805 |
| Leflunomide | 88 | $7,446 |
| MethotrexateMethotrexate Sodium | 209 | $4,365 |
| Colchicine | 43 | $2,634 |
| Famotidine | 121 | $2,437 |
| Gabapentin | 126 | $2,242 |
| Azathioprine | 39 | $1,751 |
| Sulfasalazine | 56 | $1,713 |
| Pilocarpine Hcl | 34 | $1,529 |
| Levothyroxine Sodium | 118 | $1,310 |
| ValacyclovirValacyclovir Hcl | 18 | $1,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $137,527 | $99,30219 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,008 | $61,27511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Tulsa
- Mary Hinojos MamutTulsa$21K
- Manuel CalvinTulsa$19K
- Alan MartinTulsa$18K
- William SurbeckTulsa$17K
- Michael MalloyTulsa$13K
- Ellen ZanetakisTulsa$10K
- Basmah JalilTulsa$10K
- Priyatha GarlapatiTulsa$8K
- James McKayTulsa$5K
- Lindsay CunninghamTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.